Open Nav


  • Anton Buzdin, Omicsway

Omicsway is specialized on advanced bioinformatics of gene expression data. Our major area is finding molecular markers of tumor response to target therapy. We use original algorithms for quantitative measuring molecular pathway activation based on high throughput gene expression data. We built a proprietary database of >3.000 human molecular pathways with ~10.000 genes involved, and uniformly annotated function of each gene product in every pathway. Pathway activation strength is calculated and used as predictor of tumor response to target drugs. We generated second-opinion system for clinical oncologists and tested it in clinical investigation for a prospective cohort of recurrent/metastatic tumor patients. ~46% of off-label prescriptions were made based on this second opinion system, showing short-term observed objective response in ~60% of the cases. We seek for partnerships to promote our second opinion system Oncobox in the specific fields of colorectal, kidney and brain tumors.

  • Date:Tuesday, March 5
  • Time:2:15 PM - 2:30 PM
  • Room:Drawing Room
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Submission ID:22994
  • Goal for Presentation:To find investors, clinical and legal partners
  • Company Website:
  • Company HQ City:Walnut
  • Company HQ State:California
  • Company HQ Country:United States
  • CEO/Top Company Official:Andrew Garazha
  • Year Founded:2017
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:Second opinion molecular test system for personalization of target drugs prescription
  • Development Phase of Primary Product:Phase I
Anton Buzdin